KYMERA THERAPEUTICS, INC. Finance Lease, Right-of-Use Asset, Amortization
KYMERA THERAPEUTICS, INC. (KYMR) reported Finance Lease, Right-of-Use Asset, Amortization of $430.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-08-05
- KYMERA THERAPEUTICS, INC. finance lease, right-of-use asset, amortization for the quarter ending 2026-06-30 was $430.00K, a 14.67% increase year-over-year.
- KYMERA THERAPEUTICS, INC. finance lease, right-of-use asset, amortization for the quarter ending 2026-03-31 was $430.00K, a 15.90% increase year-over-year.
- KYMERA THERAPEUTICS, INC. finance lease, right-of-use asset, amortization for the quarter ending 2025-12-31 was $430.00K, a 36.51% increase year-over-year.
- KYMERA THERAPEUTICS, INC. finance lease, right-of-use asset, amortization for the quarter ending 2025-09-30 was $440.00K, a 40.13% increase year-over-year.
- KYMERA THERAPEUTICS, INC. finance lease, right-of-use asset, amortization for fiscal 2025 was $1.62M, a 13.48% increase from fiscal 2024.
- KYMERA THERAPEUTICS, INC. finance lease, right-of-use asset, amortization for fiscal 2024 was $1.42M, a 5.07% decline from fiscal 2023.
- KYMERA THERAPEUTICS, INC. finance lease, right-of-use asset, amortization for fiscal 2023 was $1.50M, a 25.00% increase from fiscal 2022.
- KYMERA THERAPEUTICS, INC. finance lease, right-of-use asset, amortization for fiscal 2022 was $1.20M, a 33.33% increase from fiscal 2021.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 3 month as first filed | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month | Finance Lease, Right-of-Use Asset, Amortization 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $430.00K 10-Q · filed 2026-08-05 | $861.00K 10-Q · filed 2026-08-05 | $1.29M derived: sum of 3 quarters · filed 2026-08-05 | $1.73M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2026-03-31 | $430.00K 10-Q · filed 2026-04-30 | $860.00K derived: sum of 2 quarters · filed 2026-04-30 | $1.30M derived: sum of 3 quarters · filed 2026-04-30 | $1.68M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-12-31 | $430.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $870.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.25M derived: sum of 3 quarters · filed 2026-08-05 | $1.62M 10-K · filed 2026-02-26 | ||
| 2025-09-30 | $440.00K 10-Q · filed 2025-11-04 | $815.00K derived: sum of 2 quarters · filed 2026-08-05 | $1.19M 10-Q · filed 2025-11-04 | $1.50M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-06-30 | $375.00K 10-Q · filed 2026-08-05 | $746.00K 10-Q · filed 2026-08-05 | $1.06M derived: sum of 3 quarters · filed 2026-08-05 | $1.38M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $371.00K 10-Q · filed 2026-04-30 | $686.00K derived: sum of 2 quarters · filed 2026-04-30 | $1.00M derived: sum of 3 quarters · filed 2026-04-30 | $1.38M derived: sum of 4 quarters · filed 2026-04-30 | ||
| 2024-12-31 | $315.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $629.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.01M derived: sum of 3 quarters · filed 2026-02-26 | $1.42M 10-K · filed 2026-02-26 | ||
| 2024-09-30 | $314.00K 10-Q · filed 2025-11-04 | $695.00K derived: sum of 2 quarters · filed 2025-11-04 | $1.11M 10-Q · filed 2025-11-04 | $1.49M derived: sum of 4 quarters · filed 2026-04-30 | ||
| 2024-06-30 | $381.00K 10-Q · filed 2025-08-11 | $795.00K 10-Q · filed 2025-08-11 | $1.17M derived: sum of 3 quarters · filed 2026-04-30 | $1.54M derived: sum of 4 quarters · filed 2026-04-30 | ||
| 2024-03-31 | $400.00K 10-Q · filed 2026-04-30 | $414.00K 10-Q · filed 2024-05-02 | $792.00K derived: sum of 2 quarters · filed 2026-04-30 | $1.16M derived: sum of 3 quarters · filed 2026-04-30 | $1.53M derived: sum of 4 quarters · filed 2026-04-30 | |
| 2023-12-31 | $392.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $761.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.13M derived: sum of 3 quarters · filed 2026-02-26 | $1.50M 10-K · filed 2026-02-26 | $1.48M 10-K · filed 2024-02-22 | |
| 2023-09-30 | $369.00K 10-Q · filed 2024-10-31 | $739.00K derived: sum of 2 quarters · filed 2024-10-31 | $1.11M 10-Q · filed 2024-10-31 | $1.45M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-06-30 | $370.00K 10-Q · filed 2024-08-07 | $739.00K 10-Q · filed 2024-08-07 | $1.08M derived: sum of 3 quarters · filed 2025-02-27 | $1.38M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-03-31 | $369.00K 10-Q · filed 2024-05-02 | $714.00K derived: sum of 2 quarters · filed 2025-02-27 | $1.01M derived: sum of 3 quarters · filed 2025-02-27 | $1.29M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2022-12-31 | $345.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $642.00K derived: sum of 2 quarters · filed 2025-02-27 | $921.00K derived: sum of 3 quarters · filed 2025-02-27 | $1.20M 10-K · filed 2025-02-27 | $1.18M 10-K · filed 2023-02-23 | |
| 2022-09-30 | $297.00K 10-Q · filed 2023-11-02 | $576.00K derived: sum of 2 quarters · filed 2023-11-02 | $855.00K 10-Q · filed 2023-11-02 | $1.10M derived: sum of 4 quarters · filed 2024-02-22 | ||
| 2022-06-30 | $279.00K 10-Q · filed 2023-08-03 | $558.00K 10-Q · filed 2023-08-03 | $808.00K derived: sum of 3 quarters · filed 2024-02-22 | $1.09M derived: sum of 4 quarters · filed 2024-02-22 | ||
| 2022-03-31 | $279.00K 10-Q · filed 2023-05-04 | $529.00K derived: sum of 2 quarters · filed 2024-02-22 | $808.00K derived: sum of 3 quarters · filed 2024-02-22 | $1.00M derived: sum of 4 quarters · filed 2024-02-22 | ||
| 2021-12-31 | $250.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $529.00K derived: sum of 2 quarters · filed 2024-02-22 | $722.00K derived: sum of 3 quarters · filed 2024-02-22 | $900.00K 10-K · filed 2024-02-22 | $906.00K 10-K · filed 2022-02-24 | |
| 2021-09-30 | $279.00K 10-Q · filed 2022-11-03 | $472.00K derived: sum of 2 quarters · filed 2022-11-03 | $650.00K 10-Q · filed 2022-11-03 | $811.00K derived: sum of 4 quarters · filed 2023-02-23 | ||
| 2021-06-30 | $193.00K 10-Q · filed 2022-08-09 | $371.00K 10-Q · filed 2022-08-09 | $532.00K derived: sum of 3 quarters · filed 2023-02-23 | $715.00K derived: sum of 4 quarters · filed 2023-02-23 | ||
| 2021-03-31 | $178.00K 10-Q · filed 2022-05-03 | $339.00K derived: sum of 2 quarters · filed 2023-02-23 | $522.00K derived: sum of 3 quarters · filed 2023-02-23 | $717.00K derived: sum of 4 quarters · filed 2023-02-23 | ||
| 2020-12-31 | $161.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $344.00K derived: sum of 2 quarters · filed 2023-02-23 | $539.00K derived: sum of 3 quarters · filed 2023-02-23 | $700.00K 10-K · filed 2023-02-23 | $716.00K 10-K · filed 2021-03-11 | |
| 2020-09-30 | $183.00K 10-Q · filed 2021-11-10 | $378.00K derived: sum of 2 quarters · filed 2021-11-10 | $539.00K 10-Q · filed 2021-11-10 | $715.00K derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2020-06-30 | $195.00K 10-Q · filed 2021-08-06 | $356.00K 10-Q · filed 2021-08-06 | $532.00K derived: sum of 3 quarters · filed 2022-02-24 | $612.00K derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2020-03-31 | $176.00K 10-Q · filed 2021-05-06 | $337.00K derived: sum of 2 quarters · filed 2022-02-24 | $417.00K derived: sum of 3 quarters · filed 2022-02-24 | |||
| 2019-12-31 | $161.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $241.00K derived: sum of 2 quarters · filed 2022-02-24 | $400.00K 10-K · filed 2022-02-24 | $385.00K 10-K · filed 2021-03-11 | ||
| 2019-09-30 | $80.00K 10-Q · filed 2020-11-05 | $239.00K 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |